Peter Kuipers - Mar 14, 2022 Form 4 Insider Report for OMNICELL, Inc (OMCL)

Role
Executive V P& CFO
Signature
/s/ Vijay Biligiri, as attorney-in-fact for Peter J. Kuipers
Stock symbol
OMCL
Transactions as of
Mar 14, 2022
Transactions value $
-$220,433
Form type
4
Date filed
3/16/2022, 04:27 PM
Previous filing
Feb 17, 2022
Next filing
Jun 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OMCL Common Stock Award $0 +19K +39.54% $0.00 67.2K Mar 14, 2022 Direct F1
transaction OMCL Common Stock Tax liability -$220K -1.68K -2.5% $131.21 65.5K Mar 14, 2022 Direct F2
holding OMCL Common Stock 57.7K Mar 14, 2022 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects performance-based restricted stock units that were previously granted on February 9, 2021 subject to the Company meeting certain stock performance objectives compared to the NASDAQ Healthcare Index, as previously reported at the target amount of 9,520 shares on Form 4 filed on February 11, 2021. On March 14, 2022 (the determination date), the Compensation Committee determined the performance criteria was met with respect to 19,040 performance-based restricted stock units (200% of target) of which 25% vested upon the determination date. The remaining performance-based restricted stock units will vest on a semi-annual basis over a period of thirty-six months commencing on June 15, 2022.
F2 Reflects withholding of shares to cover taxes due in connection with the vesting of performance-based restricted stock units.